16 September 2026 editorial review · Trial
UST1D2: Ustekinumab phase-2/3 in adults with recent-onset T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Summary, current status, primary endpoint and key eligibility compared with the current registry. No additional discrepancy confirmed in that comparison. Historical outcome details beyond the primary sources explicitly discussed in the specialist ledgers were not all independently reverified.
Registry: NCT03941132; ACTIVE_NOT_RECRUITING; updated 2025-02-24; enrollment 66 (ESTIMATED); results not posted.
Endpoint comparison: Baseline change in 2-hour mixed meal-stimulated C-peptide AUC at week 52. (Week 52); Rate, frequency and severity of all adverse events including; hypoglycemic episodes; injection reactions; hypersensitivity reactions; evidence of infection and posterior leukoencephalopathy syndrome. (Week 52).
Sources for this record: Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2) (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.